Our science


"Under the leadership of our seasoned executive team and the guidance of world-class immuno-oncologists, iTeos is expanding its discovery engine focused on developing innovative cancer immunotherapies, with the goal of delivering at least 3 INDs over the next 3-5 years."

Michel Detheux, Ph.D.
Co-founder & CEO



iTeos’ pipeline addresses key unmet needs in immuno-oncology: to reverse immune suppression that has occurred in inflamed (hot) tumors and to increase the immunogenicity in non-inflamed (cold) tumors through stimulation of immune cell infiltration and activation of immune effector cells. These programs include:

  • Adenosine A2A receptor antagonist, about to begin clinical testing
  • TIGIT immune checkpoint blocking antibody, late stage preclinical development


iTeos focuses upon selected key mechanisms by which cancer cells suppress the immune system. The identification of these mechanisms is based on gene expression profiles of immune cell subsets as they recognize tumor cell targets, protein expression in human tumors and demonstration of proof of concept by blocking these mechanisms in a variety of laboratory models.

iTeos continues to work on target discovery to fuel its expanding portfolio of therapeutic programs in immune-oncology. iTeos has developed an innovative in vitro phenotyping screening assay that mimics the tumor microenvironment. This target identification platform is used to identify novel targets and rational combinations with our current programs. Collaborations to allow access to and to profile immune cells within patient tumors allows us to provide the relevant disease context for our current and future targets.